Birgitte Krogsgaard

MD, PhD. Postdoc at Aarhus University / Dept. of Cardiology, Aarhus University Hospital, Denmark. Investigating image-based coronary physiology @FAVORIIITrial

[PCRonline 🫀 @PCRonline]

Coronary revascularisation deferral based on QFR or FFR: a post-hoc analysis 🔎 of the FAVOR III Europe trial

@drgocchipinti & @sbrugaletta review ✍️ this analysis that found that QFR-based deferral of coronary artery revascularisation resulted in a higher incidence of 1-year MACE as compared with FFR-based deferral.

https://t.co/w0IQdxhLHu

#EAPCI #JournalClub #interventionalcardiology

[TCTMD @TCTMD]

Deferred Revascularization Safer When Guided by FFR vs QFR: FAVOR III Europe https://t.co/u45IhjrgVj

[Birgitte Krogsgaard @B_Krogsgaard]

Important insights from the @FAVORIIITrial . Despite a 21% increase in PCI rate when using QFR, the occurrence of MACE was higher following revascularisation deferral by QFR than by FFR. @JEscaned @NielsRHolm @h_evald

[EuroIntervention @EuroInterventio]

❌NEW AHEAD OF PRINT❌
"Coronary revascularisation deferral based on quantitative flow ratio or fractional flow reserve: a post hoc analysis of the FAVOR III Europe trial" @JEscaned
#Cardiology #CoronaryArteryDisease #PCI #ClinicalResearch
Read the full article: https://t.co/BITMrr4Oxq

[Birgitte Krogsgaard @B_Krogsgaard]

@AshkanEftekhar1 @FAVORIIITrial @TheLancet @NielsRHolm @h_evald Thank you, Ashkan! Looking forward to further collaborations 🙏🏼

[Birgitte Krogsgaard @B_Krogsgaard]

I am proud of our team work in both conducting and reporting the @FAVORIIITrial. Publication is now available online in @TheLancet

@NielsRHolm @h_evald

[The Lancet @TheLancet]

Presented today at #TCT2024:

Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial https://t.co/nJmCjKe6y8 @TCTConference

[Birgitte Krogsgaard @B_Krogsgaard]

@AnneDybro @NielsRHolm @h_evald Tusind tak Anne! 🙌🏼

[Birgitte Krogsgaard @B_Krogsgaard]

A great summary of the findings in the @FAVORIIITrial by @TCTMD, with important comments by @mmamas1973 and @JoostDaemen
Several substudies in the pipeline - hopefully adding further insights soon.

#TCT2024 #QFR #RCT #CardioTwitter

[TCTMD @TCTMD]

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe https://t.co/ODCgpY8qHG

[Birgitte Krogsgaard @B_Krogsgaard]

@mmamas1973 @NielsRHolm @mirvatalasnag @dr_benoy_n_shah @drptca @NickCurzen @drandrewsharp @purviparwani @iamritu @hvanspall @JGrapsa @jgranadacrf Thank you very much for your important comments and questions, adding great value to the discussion on #QFR vs. #FFR

[Mamas A. Mamas @mmamas1973]

Congratulations @NielsRHolm and @B_Krogsgaard for delivering the FAVOR III Europe Trial. Honored to provide the commentary for this presentation
@mirvatalasnag @dr_benoy_n_shah @drptca @NickCurzen @drandrewsharp @purviparwani @iamritu @hvanspall @JGrapsa @jgranadacrf

[Cardiovascular Research Foundation @crfheart]

FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at one year. Findings announced at #TCT2024 and published in @TheLancet.

https://t.co/bC9COBMt7V

#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @georgedangas @jgranadacrf @MartyBLeon @MaeharaAkiko @Drroxmehran @sahilparikhmd @triciarawh @TCTConference @jedicath @Dr_ibrahimHarbi @Almanfi_Cardio @BakhshiHooman @ABeneduceMD @nyalborgesmd @aayshacader @BCase07 @NishithChandra @baileyannRN @fischman_david @hect2701 @JGrapsa @HamidNadira @stefan_harb @AmandaLimaMD @evandrofilhobr @GiorgioMedranda @mornei2011 @SrihariNaiduMD @sumonroy_md @DocSavageTJU @Shoaib9702 @poojaotherwise @iamritu @atunuguntla1 @Pooh_Velagapudi @EZancanaroMD @AdrianaCMares @NielsRHolm @IAmDoctorAbhi @KrutarthKPandya @IndahSP_MD @ShariqShamimMD @mirvatalasnag

[Birgitte Krogsgaard @B_Krogsgaard]

@WestraJelmer @DrKoltowski @Eric_Van_Belle @GianlucaCampo78 @SimoneBiscaglia @ThueOlsen @AshkanEftekhar1 @ignamatsant @BarbaraStahli @ramonlopezpalop @HelleBargsteen @JEscaned @HernanDMejiaR @AUHCardio #TCT2024 #cardiotwitter #randomize

[Emil Nielsen Holck @EmilHolckMD]

#QFR is NOT non-inferior to #FFR. Findings from the @FAVORIIITrial at #TCT2024

@AUHCardio @NielsRHolm @B_Krogsgaard @h_evald

[Niels R. Holm @NielsRHolm]

⁦@mmamas1973⁩ summarizes the outcomes of ⁦@FAVORIIITrial⁩

[C. Michael Gibson MD @CMichaelGibson]

Angio derived Quantitative Flow Reserve inferior to wire based FFR in FAVOR 3. #TCT2024 View it here: https://t.co/Mbdbnxlztq

[Niels R. Holm @NielsRHolm]

1/x #QFR did not meet non-inferiority to FFR in the @FAVORIIITrial Europe presented by @B_Krogsgaard The 1-year primary EP of death, MI, and unplanned revasc was 6.7% vs 4.2% in favour of FFR. 21% more study-lesions were treated- and 27% more stents were implanted with QFR due to a lower median QFR of 0.81 vs 0.84 for FFR. Published online in The Lancet.
@h_evald @WestraJelmer @DrKoltowski @Eric_Van_Belle @GianlucaCampo78 @SimoneBiscaglia @ThueOlsen @AshkanEftekhar1 @ignamatsant @BarbaraStahli @ramonlopezpalop @HelleBargsteen @JEscaned @mirvatalasnag @mmamas1973 @HernanDMejiaR #TCT2024 #cardiotwitter #randomizedtrial

[Cardiovascular Research Foundation @crfheart]

Get ready to witness groundbreaking data @ #TCT2024! In collaboration with @JAMA_current this session features:
✨TRISCEND II
✨ACURATE IDE
✨FAVOR III Europe
✨FLASH
@arnoldgehrke @SusheelKodaliMD @MReardon19 @NielsRHolm @wfearonmd @npfam1 @LindaGillamMD @jgranadacrf @mmamas1973

[Emil Nielsen Holck @EmilHolckMD]

It’s late breaking day!

Watch @B_Krogsgaard from @AUHCardio presenting the main results of FAVOR III Europe at #TCT2024

It is 11:47 AM at main arena!

Watch it online here:
https://t.co/dGTJzVXESJ

[Niels R. Holm @NielsRHolm]

@TCTMD Interview with @B_Krogsgaard @wfearonmd and @mmamas1973 on the @FAVORIIITrial - LBT presentation #TCT2024 Wednesday at 11:47 EST - Details in the simultaneous publication #coronaryphysiology #randomizedtrial #cardiotwitter

[Niels R. Holm @NielsRHolm]

@FAVORIIITrial on QFR vs FFR to be presented as LBT 30. October at #TCT2024 - Methods paper here: https://t.co/cv8Wiwivov

[Niels R. Holm @NielsRHolm]

Primary endpoint of the @FAVORIIITrial on QFR vs. FFR is presented on 30. October at #TCT2024
#qfr #randomizedtrial #cardiotwitter
@B_Krogsgaard @h_evald @JEscaned @GianlucaCampo78 @DrKoltowski @gret_ziu @SejrHansen @ignamatsant @BarbaraStahli @HernanDMejiaR @llddss80 @WestraJelmer @ramonlopezpalop @ThueOlsen @SimoneBiscaglia